Moberg Pharma AB (publ) (STO:MOB)
Sweden
· Delayed Price · Currency is SEK 7.55
+0.20 (2.72%)
May 13, 2025, 5:29 PM CET
Moberg Pharma AB Company Description
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden.
It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013.
Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Moberg Pharma AB (publ)
| Country | Sweden |
| Founded | 2006 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Anna Ljung |
Contact Details
Address: Gustavslundsvägen 42 Bromma, 167 51 Sweden | |
| Phone | 46 8 52 23 07 00 |
| Website | mobergpharma.se |
Stock Details
| Ticker Symbol | MOB |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0003613090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anna Ljung BA, M.Sc. | Chief Executive Officer |
| Marie Moberg | Co-Founder |
| Mark Beveridge | Vice President of Finance |
| Dr. Christina Erixon | Head of Pharmaceutical Development and Operations |
| Dr. Amir Tavakkol Ph.D. | Chief Scientific Officer |
| Gunilla Wengström | Senior Director of Sales and Marketing |
| Anders Broijersen M.D., Ph.D. | Chief Medical Officer |
| Robert Ehrl | Head of Supply |